Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.

Jin-Xing ZhangYu-Xing ChenChun-Gao ZhouJin LiuSheng LiuHai-Bin ShiQing-Quan Zu

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

Compared to TACE-sorafenib, TACE-lenvatinib was associated with better DCR, PFS and OS outcomes in patients with unresectable HCC. In subgroups of Barcelona Clinic Liver Cancer B stage or TACE-refractory patients, TACE-lenvatinib also showed a trend of superiority.

Keyphrases

liver metastases
radiofrequency ablation
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
primary care
type diabetes
radiation therapy
adipose tissue
patient reported outcomes